ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO
NCT ID: NCT03563417
Last Updated: 2026-01-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
1560 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-11-06
Study Completion Date
2032-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study design
Prospective randomized open labeled multicenter study
Hypotheses
1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events).
2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months.
Inclusion Criteria
* CTO in native coronary artery
* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
* Age ≥18 yrs.
* Able to provide written Informed consent and willing to comply with the specified follow-up contacts
* Target artery ≥ 2.5 mm
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL \> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO
Cohort C: patients enrolled but not randomized in cohort A or B
Exclusion criteria (for both cohort A and B)
* NSTEMI or STEMI within 1 month
* Coronary anatomy not suitable for CTO-procedure
* Coronary artery disease involving the left main/three-vessel disease with indication for CABG following heart team conference
* Life expectancy \< 2 years
* Severe chronic pulmonary disease (FEV1 \< 30 % of predicted value)
* Contraindication to dual anti-platelet therapy
* Pregnancy
* eGFR \< 30 mL/min/1.73 m2
* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
* Severe valvular heart disease
Primary endpoint
Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization\*), hospitalization for heart failure or incidence of malignant arrhythmias.
\*CCS class ≥ 2 and/or QoL score \< 60. Same criteria used as for allocation to Cohort B
Cohort B: SAQ Quality of Life Assessment after 6 months.
Number of patients
1,560 (1200 in cohort A/360 in cohort B
Follow up time
Cohort A: 5 years Cohort B: 6 months
Prospective randomized open labeled multicenter study
Hypotheses
1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events).
2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months.
Inclusion Criteria
* CTO in native coronary artery
* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
* Age ≥18 yrs.
* Able to provide written Informed consent and willing to comply with the specified follow-up contacts
* Target artery ≥ 2.5 mm
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL \> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO
Cohort C: patients enrolled but not randomized in cohort A or B
Exclusion criteria (for both cohort A and B)
* NSTEMI or STEMI within 1 month
* Coronary anatomy not suitable for CTO-procedure
* Coronary artery disease involving the left main/three-vessel disease with indication for CABG following heart team conference
* Life expectancy \< 2 years
* Severe chronic pulmonary disease (FEV1 \< 30 % of predicted value)
* Contraindication to dual anti-platelet therapy
* Pregnancy
* eGFR \< 30 mL/min/1.73 m2
* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
* Severe valvular heart disease
Primary endpoint
Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization\*), hospitalization for heart failure or incidence of malignant arrhythmias.
\*CCS class ≥ 2 and/or QoL score \< 60. Same criteria used as for allocation to Cohort B
Cohort B: SAQ Quality of Life Assessment after 6 months.
Number of patients
1,560 (1200 in cohort A/360 in cohort B
Follow up time
Cohort A: 5 years Cohort B: 6 months
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction
NCT03756870
Chronic Total Occlusion of Coronary Artery
RECRUITING
NA
The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion
NCT03392415
Chronic Total Occlusion of Coronary Artery
Heart Failure
Angina Pectoris
RECRUITING
NA
Efficacy of RIPC to Reduce AKI for Patients Undergoing PCI
NCT02195726
Acute Kidney Injury
COMPLETED
PHASE4
Antithrombotic Management of Acute Mesenteric Ischaemia
NCT05706012
Acute Mesenteric Ischemia
Short Bowel Syndrome
COMPLETED
Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease
NCT03621501
Acute Coronary Syndrome
ACTIVE_NOT_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A chronic total occlusion (CTO) is observed in up to (1) 30 % of patients undergoing diagnostic coronary angiography. The presence of a CTO is associated with worse outcome compared to non-occlusive coronary artery disease.
Percutaneous Coronary Intervention (PCI) treatment of CTO lesions has gained much attention over the last decade due to introduction of new techniques and devices resulting in high success rates in dedicated centers. However the scientific evidence is mainly based on observational studies and expert consensus. The current European and American guidelines on revascularization does not provide any clear recommendations how to manage patients with CTO.
The indication of treating a CTO lesion, or any other lesion with PCI for that matter, is either to relieve symptoms or improve prognosis. However, to date, there are no randomized clinical trials showing any prognostic benefit from CTO revascularization. Data from randomized clinical trials are also scarce regarding improvement of symptoms and Quality of life (QoL). In the recently presented DECISION-CTO study, patients were randomized to PCI vs. OMT, and the study failed to demonstrate a prognostic or symptomatic benefit of PCI vs. OMT. However, the study was prematurely terminated due to slow inclusion rate and had a high crossover rate and a high proportion did not have a quality of life score at follow-up. The fact that both the Decision CTO and the Euro CTO trial failed to include the pre-specified number of patients, makes it difficult to draw any conclusions on how to treat these patients. The preliminary results from both trials indicate that CTO PCI seems to be a safe procedure and might improve symptoms and QoL. In the randomized EXPLORE trial, patients with ST-elevation myocardial infarction (STEMI)and a concomitant CTO in a non infarct related artery was investigated. This study showed no benefit in terms of improving left ventricular function due to CTO-PCI of the concomitant CTO, although the procedure was safe.
Meta-analysis of observational studies comparing the prognosis after successful vs. unsuccessful CTO PCI indicate prognostic and symptomatic benefit of successful CTO PCI. However, these studies often lack data regarding ischemia burden and viability. The fact that the non-successful PCI patients consistently in these studies have higher risk profile, indicating the presence of residual confounders not accounted for in the multivariate statistical models, makes the interpretation of these data in a clinical setting difficult. The non-randomized FACTOR trial demonstrated a positive outcome for quality of life, but only in symptomatic patients. Data from the OPEN-CTO registry demonstrated an improvement of the Seattle Angina Questionnaire for quality of life by 10.8 points after a successful CTO-procedure. In addition to symptomatic improvement, a successful CTO procedure can reduce the amount of myocardium susceptible to ischemia in patients with at least mild to moderate ischemia at baseline and by that the prognosis can be improved (mortality, myocardial infarction, ventricular arrhythmias).
Hence, the interventional management of CTO lesions must address whether it is indicated on symptomatic and/or prognostic basis. These questions have not been sufficiently addressed in the previous trials and we need evidence from randomized clinical trials on how to treat these patients. We therefore designed this randomized clinical trial addressing the impact of CTO PCI on outcome. Patients are included in 2 different patient cohorts depending on level of symptoms and level of myocardial ischemia. From previous studies, we know that it is most probably only patients with at least moderate myocardial ischemia who will benefit from CTO PCI in terms of improving MACCE, and only symptomatic patients who will benefit with regard to improvement of quality of life following CTO PCI.
Before entering the study all patients will be subject to a 3-month period with titration of optimal medical therapy. Hereafter the patients will be eligible for inclusion in one of two cohorts based on level of ischemia and presence of symptoms:
Cohort A: Comprise CTO patients who are asymptomatic (CCS class \<2 and SAQ QoL\> 60) but have moderate myocardial ischemia (\>10% of the left ventricle) on MR or rubidium-PET. These patients will be randomized to CTO PCI or OMT and followed up to 10 years.
Cohort B: Comprise symptomatic CTO patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60) with at least 5% reversible ischemia. These patients will be randomized to CTO PCI or OMT. The patients randomized to OMT will be offered CTO PCI procedure 6 months after randomization following assessment of Seattle Angina Questionnaire quality of life score.
Cohort C - Patients enrolled but not eligible for randomization All patients enrolled at baseline but who do not meet the criteria described in cohort A and B for randomization. Registry based follow-up (optional) is performed at the same time points as in Cohort A.
This is the first randomized study that addresses improvement of prognosis and quality of life following PCI of CTO lesions specifically.
The purpose of this study is twofold:
1. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with significant myocardial ischemia (≥ 10%) without symptoms
2. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with symptoms and mild to moderate myocardial ischemia (≥5%).
Hypotheses
1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of outcome measured as 30% relative reduction in Major Adverse Cardiovascular and Cerebrovascular events (MACCE).
2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of improved life quality measured as an increase of SAQ score of 8 points after 6 months.
Percutaneous Coronary Intervention (PCI) treatment of CTO lesions has gained much attention over the last decade due to introduction of new techniques and devices resulting in high success rates in dedicated centers. However the scientific evidence is mainly based on observational studies and expert consensus. The current European and American guidelines on revascularization does not provide any clear recommendations how to manage patients with CTO.
The indication of treating a CTO lesion, or any other lesion with PCI for that matter, is either to relieve symptoms or improve prognosis. However, to date, there are no randomized clinical trials showing any prognostic benefit from CTO revascularization. Data from randomized clinical trials are also scarce regarding improvement of symptoms and Quality of life (QoL). In the recently presented DECISION-CTO study, patients were randomized to PCI vs. OMT, and the study failed to demonstrate a prognostic or symptomatic benefit of PCI vs. OMT. However, the study was prematurely terminated due to slow inclusion rate and had a high crossover rate and a high proportion did not have a quality of life score at follow-up. The fact that both the Decision CTO and the Euro CTO trial failed to include the pre-specified number of patients, makes it difficult to draw any conclusions on how to treat these patients. The preliminary results from both trials indicate that CTO PCI seems to be a safe procedure and might improve symptoms and QoL. In the randomized EXPLORE trial, patients with ST-elevation myocardial infarction (STEMI)and a concomitant CTO in a non infarct related artery was investigated. This study showed no benefit in terms of improving left ventricular function due to CTO-PCI of the concomitant CTO, although the procedure was safe.
Meta-analysis of observational studies comparing the prognosis after successful vs. unsuccessful CTO PCI indicate prognostic and symptomatic benefit of successful CTO PCI. However, these studies often lack data regarding ischemia burden and viability. The fact that the non-successful PCI patients consistently in these studies have higher risk profile, indicating the presence of residual confounders not accounted for in the multivariate statistical models, makes the interpretation of these data in a clinical setting difficult. The non-randomized FACTOR trial demonstrated a positive outcome for quality of life, but only in symptomatic patients. Data from the OPEN-CTO registry demonstrated an improvement of the Seattle Angina Questionnaire for quality of life by 10.8 points after a successful CTO-procedure. In addition to symptomatic improvement, a successful CTO procedure can reduce the amount of myocardium susceptible to ischemia in patients with at least mild to moderate ischemia at baseline and by that the prognosis can be improved (mortality, myocardial infarction, ventricular arrhythmias).
Hence, the interventional management of CTO lesions must address whether it is indicated on symptomatic and/or prognostic basis. These questions have not been sufficiently addressed in the previous trials and we need evidence from randomized clinical trials on how to treat these patients. We therefore designed this randomized clinical trial addressing the impact of CTO PCI on outcome. Patients are included in 2 different patient cohorts depending on level of symptoms and level of myocardial ischemia. From previous studies, we know that it is most probably only patients with at least moderate myocardial ischemia who will benefit from CTO PCI in terms of improving MACCE, and only symptomatic patients who will benefit with regard to improvement of quality of life following CTO PCI.
Before entering the study all patients will be subject to a 3-month period with titration of optimal medical therapy. Hereafter the patients will be eligible for inclusion in one of two cohorts based on level of ischemia and presence of symptoms:
Cohort A: Comprise CTO patients who are asymptomatic (CCS class \<2 and SAQ QoL\> 60) but have moderate myocardial ischemia (\>10% of the left ventricle) on MR or rubidium-PET. These patients will be randomized to CTO PCI or OMT and followed up to 10 years.
Cohort B: Comprise symptomatic CTO patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60) with at least 5% reversible ischemia. These patients will be randomized to CTO PCI or OMT. The patients randomized to OMT will be offered CTO PCI procedure 6 months after randomization following assessment of Seattle Angina Questionnaire quality of life score.
Cohort C - Patients enrolled but not eligible for randomization All patients enrolled at baseline but who do not meet the criteria described in cohort A and B for randomization. Registry based follow-up (optional) is performed at the same time points as in Cohort A.
This is the first randomized study that addresses improvement of prognosis and quality of life following PCI of CTO lesions specifically.
The purpose of this study is twofold:
1. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with significant myocardial ischemia (≥ 10%) without symptoms
2. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with symptoms and mild to moderate myocardial ischemia (≥5%).
Hypotheses
1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of outcome measured as 30% relative reduction in Major Adverse Cardiovascular and Cerebrovascular events (MACCE).
2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of improved life quality measured as an increase of SAQ score of 8 points after 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Ischemic Heart Disease
Chronic Total Occlusion of Coronary Artery
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCI
Group Type
ACTIVE_COMPARATOR
Percuteneous Coronary Intervention
Intervention Type
PROCEDURE
PCI of Chronic Total Occlusions
OMT
Group Type
OTHER
Optimal Medical Therapy
Intervention Type
OTHER
Initiation and titration of optimal medical therapy in the control arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Percuteneous Coronary Intervention
PCI of Chronic Total Occlusions
Intervention Type
PROCEDURE
Optimal Medical Therapy
Initiation and titration of optimal medical therapy in the control arm.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CTO in native coronary artery
* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
* Age ≥18 yrs.
* Able to provide written informed consent and willing to comply with the specified follow-up contacts.
* Target artery ≥ 2.5 mm
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL \> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.
Cohort C: Screening population not eligible for randomization in cohort A or B
* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
* Age ≥18 yrs.
* Able to provide written informed consent and willing to comply with the specified follow-up contacts.
* Target artery ≥ 2.5 mm
Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:
Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL \> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO
Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.
Cohort C: Screening population not eligible for randomization in cohort A or B
Exclusion Criteria
* NSTEMI or STEMI within 1 month
* Coronary anatomy not suitable for CTO-procedure
* Coronary disease involving the left main/three vessel disease with indication for CABG following heart team conference.
* Life expectancy \< 2 years
* Severe chronic pulmonary disease (FEV1 \< 30 % of predicted value)
* Contraindication to dual anti-platelet therapy
* Pregnancy
* eGFR \< 30 mL/min/1.73 m2
* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
* Severe valvular heart disease
* Coronary anatomy not suitable for CTO-procedure
* Coronary disease involving the left main/three vessel disease with indication for CABG following heart team conference.
* Life expectancy \< 2 years
* Severe chronic pulmonary disease (FEV1 \< 30 % of predicted value)
* Contraindication to dual anti-platelet therapy
* Pregnancy
* eGFR \< 30 mL/min/1.73 m2
* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
* Severe valvular heart disease
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital Skejby
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Evald Hoej Christiansen
Consultant MD PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Evald Christiansen, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus N, , Denmark
Site Status
RECRUITING
Rigshospitalet
Copenhagen, , Denmark
Site Status
RECRUITING
Gentofte Hospital
Hellerup, , Denmark
Site Status
RECRUITING
Odense University Hospital
Odense, , Denmark
Site Status
RECRUITING
Zealand University Hospital
Roskilde, , Denmark
Site Status
RECRUITING
North-Estonia Medical Centre
Tallinn, , Estonia
Site Status
RECRUITING
Helsinki University Central Hospital
Helsinki, , Finland
Site Status
ACTIVE_NOT_RECRUITING
Kuopio University Hospital
Kuopio, , Finland
Site Status
ACTIVE_NOT_RECRUITING
Heart Hospital Tampere
Tampere, , Finland
Site Status
RECRUITING
Turku University Hospital
Turku, , Finland
Site Status
RECRUITING
Clinique Louis Pasteur
Essey-lès-Nancy, , France
Site Status
ACTIVE_NOT_RECRUITING
Cardiovascular Institute, Groupe Hospitalier Mutualiste
Grenoble, , France
Site Status
RECRUITING
Hospital Germans Trias I Pujol
Badalona, Barcelona, Spain
Site Status
ACTIVE_NOT_RECRUITING
Hospital Galdakao
Galdakao, Bizkaia, Spain
Site Status
RECRUITING
Hospital Vall de Hebron
Barcelona, , Spain
Site Status
ACTIVE_NOT_RECRUITING
Hospital Clinic
Barcelona, , Spain
Site Status
RECRUITING
Hospital de Bellvitge
Barcelona, , Spain
Site Status
ACTIVE_NOT_RECRUITING
Hospital Universitario Clinico San Carlos
Madrid, , Spain
Site Status
RECRUITING
Hospital la Paz
Madrid, , Spain
Site Status
ACTIVE_NOT_RECRUITING
Hospital Universitari de Tarragona Joan XXIII
Tarragona, , Spain
Site Status
RECRUITING
Sahlgrenska University Hospital
Gothenburg, , Sweden
Site Status
RECRUITING
Skaane University Hospital (Lund)
Lund, , Sweden
Site Status
ACTIVE_NOT_RECRUITING
Stockholm South Central Hospital (Södersjukhuset)
Stockholm, , Sweden
Site Status
ACTIVE_NOT_RECRUITING
Belfast Health and Social Care Trust, Department of Cardiology
Belfast, , United Kingdom
Site Status
ACTIVE_NOT_RECRUITING
University Hospital Bristol
Bristol, , United Kingdom
Site Status
ACTIVE_NOT_RECRUITING
Barts Health NHS
London, , United Kingdom
Site Status
ACTIVE_NOT_RECRUITING
St George's University Hospital
London, , United Kingdom
Site Status
ACTIVE_NOT_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Estonia
Finland
France
Spain
Sweden
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rinfret S, Sandesara PB. Reducing Ischemia With CTO PCI: Good News, But Questions Remain. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1419-1422. doi: 10.1016/j.jcin.2021.05.028. No abstract available.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISCHEMIA-CTO Trial
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction
NCT03156816
COMPLETED
PHASE2
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
NCT05160311
UNKNOWN
NA
RadIal Versus Femoral InvEstigation in ST Elevation Acute Coronary Syndrome
NCT01420614
UNKNOWN
NA
DCB Under the Guidance of OCT in STEMI
NCT05680051
UNKNOWN
NA
The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease
NCT01508663
UNKNOWN
PHASE4
Remote Ischemic Preconditioning in Primary PCI
NCT00435266
COMPLETED
PHASE2/PHASE3
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
NCT06465303
RECRUITING
PHASE2
Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study
NCT01665365
UNKNOWN
NA
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
NCT01471522
COMPLETED
NA
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
NCT01374321
COMPLETED
PHASE2
Arterial Access for Coronary Intervention in Myocardial Infarction
NCT00356044
COMPLETED
PHASE4
Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients
NCT05193019
RECRUITING
Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia
NCT04685941
COMPLETED
NA
Thrombectomy and Improvement of Left Ventricular Function in AMI
NCT00288665
COMPLETED
PHASE4
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
NCT00379418
COMPLETED
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
NCT00275990
COMPLETED
PHASE4
Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction
NCT07181356
RECRUITING
NA
Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions
NCT01158716
COMPLETED
NA
Local Thrombolytics Before Thrombectomy in STEMI
NCT01568931
UNKNOWN
PHASE4
Impact of PREVENTIVE Substrate Ablation of Coronary Chronic Total Occlusion on Implantable cardioVerTer-Defibrillator Interventions
NCT03421834
COMPLETED
NA
Thrombectomy in Acute Myocardial Infarction
NCT00675480
COMPLETED
PHASE3
Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction
NCT00766740
COMPLETED
PHASE4
Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours
NCT00260416
COMPLETED
PHASE2
Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery
NCT06175377
NOT_YET_RECRUITING
NA